January 27, 2016.
FDA News reports that Roche is cooperating with inquiries from the Indian states of Gujarat and Telangana, where sales of its cancer drug Avastin have been halted after 15 patients experienced adverse effects.
It was reported a week ago that Gujarat and Telangana had put sales of Avastin on hold while they investigated further. Patients in these regions had received Avastin for vision problems. While the drug was not approved for this purpose, it has been used off-label worldwide to treat advanced age-related macular degeneration.
Roche has since said in a statement that off-label use of Avastin “bears the risk of contamination and has already led to serious bacterial infections of the eye in other countries around the world.”
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.